Back to Journals » Infection and Drug Resistance » Volume 5

Evaluation of the use of piperacillin/tazobactam (Tazocin®) at Hamad General Hospital, Qatar: are there unjustified prescriptions?

Authors Khan F , Elhiday A, Khudair IF, Yousef H, Hussein Omran A, Alsamman SH, Elhamid M

Received 5 November 2011

Accepted for publication 30 November 2011

Published 13 January 2012 Volume 2012:5 Pages 17—21


Review by Single anonymous peer review

Peer reviewer comments 4

Fahmi Yousef Khan1, Abdelhaleem Elhiday1, Imran Fahmi Khudair2, Hind Yousef3, Aisha Hussein Omran4, Samer Hytham Alsamman1, Maha Elhamid2
1Department of Medicine, 2Clinical Service, Pharmacy Department, 3Endocrine Division, Department of Medicine, 4Chest Team, Department of Medicine, Hamad General Hospital, Doha, Qatar

Objectives: The aim of this study was to evaluate the appropriateness of piperacillin/tazobactam (Tazocin®; Pfizer, New York, NY) usage in our hospital.
Subjects and methods: This retrospective study was designed to involve all patients admitted to Hamad General Hospital and prescribed piperacillin/tazobactam as an empiric therapy from January 1 to March 31, 2008. The medical records of such patients were retrospectively reviewed and studied.
Results: During this period, 610 prescriptions were ordered for 596 patients. The main indication for initiation of Tazocin was sepsis (207/610; 34%). The overall rate of appropriateness of empirical therapy was 348/610 (57%). Most of the inappropriate prescriptions were in cases of aspiration pneumonia and abdominal infections, with inappropriate prescriptions found mostly in surgical wards (86%) and the surgical intensive care unit (66.7%). Septic work-up results showed positive cultures in 57% (345/610) of cases. There were 198/254 prescriptions (78%) where antibiotics were changed according to the sensitivity data to narrow-spectrum antimicrobials. In 56/254 (22%) cases, pathogens were susceptible to narrow-spectrum antibiotics even though piperacillin/tazobactam was continued.
Conclusion: Our study showed that there was an injudicious use of piperacillin/tazobactam at our hospital, evidenced by the significant number of inappropriate empiric prescriptions and inappropriate drug modifications, based on the results of microbial cultures and antibiograms.

Keywords: piperacillin/tazobactam, empiric therapy, appropriate use, broad-spectrum antibiotics

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.